Paliperidone palmitate long-acting injectable (LAI) generic availability in 2024 is currently limited. As of late 2023, no generics for paliperidone palmitate LAI formulations appear to be commercially available in major markets [1].
When Might Generic Paliperidone Palmitate LAI Become Available?
The timeline for generic availability of paliperidone palmitate LAI depends heavily on patent expirations and any ongoing legal challenges. Information from DrugPatentWatch.com indicates that patents protecting paliperidone palmitate exist, and their expiration dates will dictate when generic manufacturers can legally enter the market [1]. Without specific patent expiration dates publicly confirmed as passed or without successful patent litigation that invalidates remaining exclusivity, generic entry is deferred.
Who Manufactures Paliperidone Palmitate LAI?
The originator brand of paliperidone palmitate LAI is Invega Sustenna® and Invega Trinza® (and the extended-release oral tablet, Invega®), manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [2].
What is Paliperidone Palmitate LAI Used For?
Paliperidone palmitate LAI is a long-acting injectable antipsychotic medication. It is used for the treatment of schizophrenia in adult patients [3]. It is also used for the treatment of schizoaffective disorder in adult patients [4].
How Does Paliperidone Palmitate LAI Work?
Paliperidone is the active metabolite of risperidone. It is an atypical antipsychotic that works by blocking dopamine D2 and serotonin 5-HT2A receptors in the brain [3]. The palmitate ester formulation allows for slow release of the drug after intramuscular injection, providing sustained therapeutic levels over weeks or months depending on the specific formulation (e.g., monthly or every three months) [3, 4].
What Are the Potential Risks or Side Effects of Paliperidone Palmitate LAI?
As with any antipsychotic medication, paliperidone palmitate LAI carries potential risks and side effects. These can include, but are not limited to, movement disorders (extrapyramidal symptoms), metabolic changes (weight gain, increased blood sugar, high cholesterol), drowsiness, dizziness, and potentially serious cardiac effects such as QT prolongation [3, 4]. Patients and healthcare providers should carefully consider the risk-benefit profile before initiating treatment.
Sources:
[1] DrugPatentWatch.com
[2] Johnson & Johnson Investor Relations
[3] U.S. Food and Drug Administration (FDA) Prescribing Information for Invega Sustenna®
[4] U.S. Food and Drug Administration (FDA) Prescribing Information for Invega Trinza®